Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Organon & Co posts solid Q4 results, eyes biosimilar launches

Organon & Co delivered a strong financial performance in Q4 2024, driven by revenue growth and operational efficiency. Despite challenges like biosimilar decline and LOE impact, the company remains focused on sustaining growth and optimizing cost structures. Strategic initiatives, including biosimilar launches and cost-saving measures, position Organon for continued success and market resilience in 2025. With a solid foundation and growth strategy in place, Organon is poised to navigate challenges and capitalize on opportunities for long-term value creation.

Organon & Co reports strong Q1 results, eyes growth opportunities

Organon & Co's Q1 2025 earnings call showcased a robust performance, with a focus on key product success, financial stability, and strategic growth initiatives. While facing challenges such as sales targets and tariff impacts, the company's strengths in diverse portfolios and cost-saving measures provide a solid foundation for future growth. By capitalizing on opportunities and addressing challenges effectively, Organon is poised for continued success in the market.

Organon & Co reports resilient Q2 performance and raises revenue guidance

Organon & Co delivered a solid performance in Q2, with key segments showing growth and a strong financial position reflected in debt repayment and guidance updates. While facing challenges such as revenue decline and financial targets, the company's strengths in innovation and market presence position it well for future opportunities. With a focus on strategic growth areas and financial discipline, Organon & Co aims to navigate challenges and leverage opportunities for sustainable long-term success. Investors can be optimistic about Organon & Co's performance and strategic direction, considering its resilience, growth prospects, and commitment to financial stability.

Organon & Co reports robust Q3 earnings amidst growth challenges

Organon & Co's Q3 earnings call highlighted strong revenue, operational performance, and strategic focus. The company addressed challenges in sales practices and Nexplanon growth while emphasizing opportunities for future development.

Organon & Co reports solid 2025 results, eyes stable growth

Organon & Co's 2025 performance showcased revenue and EBITDA strength, driven by biosimilars and cost-saving initiatives. While facing challenges in certain segments like Nexplanon, the company is redirecting savings to drive revenue growth opportunities. With a focus on maintaining volume growth, stabilizing established brands, and reducing leverage, Organon aims for a steady performance in 2026.